Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients

Antiviral Therapy

Volumn 1, Issue 3, 1996, Pages 172-179

  Noormohamed, Faniq H ^a   Youle, Michael S ^a   Tang, Boyuk ^a   Martin Munley, Sarah ^b   Gazzard, Brian G ^a   Lant, Ariel F ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Astra USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CALCIUM; FOSCARNET; MAGNESIUM;

ADULT; ARTICLE; BLOOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; CALCIUM; FOSCARNET; HIV SEROPOSITIVITY; HUMANS; MAGNESIUM; MALE; MIDDLE AGED;

EID: 0030201568     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Katlama C, Dohin E, Caumes E, Cochereau-Massin I, Brancon C, Robinet M, Rogeaux O, Dahan R & Gentilini M. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimes. Journal of Acquired Immune Deficiency Syndromes 1992; 5(Suppl. 1):S18-S24.
2. Blanshard C. Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. Journal of Acquired Immune Deficiency Syndromes 1992; 5(Suppl. 1):S25-S28.
3. Palestine AG, Polis MA, De Smet MD, Baird BF, Falloon J, Kovacs JA, Davey RT, Zurlo JJ, Zunich KM, Davis M, Hubbard L, Brothers R, Ferris FL, Chew E, Davis JL, Rubin BI, Mellow SD, Metcalf JA, Manischewitz J, Minor JR, Nussenblatt RB, Masur H & Lane HC. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Annals of Internal Medicine 1991; 115:665-673.
4. Polis MA, De Smet MD, Baird BF, Mellow SD, Falloon J, Davey RT, Kovacs JA, Palestine AG, Nussenblatt RB, Masur H & Lane HC. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). American Journal of Medicine 1993; 94:175-180.
5. Spector SA, McKinley GS, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R & Stempien MJ. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. New England Journal of Medicine 1996; 334:1491-1497.
6. Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, Falloon J, Davey RT Jr, Kovacs JA, Walker RE, Whitcup SM, Nussenblatt RB, Lane HC & Masur H. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrobial Agents and Chemotherapy 1995; 39:882-886
7. Kirsch LS, Arevalo JF, De Clercq E, Chavez de la Paz E, Munguia D, Garcia R & Freeman WR. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. American Journal of Ophthalmology 1995; 119:466-476.
8. Jacobson MA. Review of the toxicities of foscarnet. Journal of Acquired Immune Deficiency Syndromes 1992; 5(Suppl. 1):S11-S17.
9. Seidel EA, Koenig S & Polis MA. A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. AIDS (Philadelphia) 1993; 7:941-945.
10. Chrisp P & Clissold SP. Foscarnet. Drugs 1991; 41:104-129.
11. Youle MS, Clarbour J, Gazzard B & Chanas A. Severe hypocalcaemia m AIDS patients treated with foscarnet and pentamidine. Lancet 1988; i:1455-1466.
12. Jacobson MA, O'Donnell JJ & Mills J. Foscarnet treatment of cytomegalovirus in patients with acquired immunodeficiency syndrome. Antimicrobial Agents and Chemotherapy 1989; 33:736-741.
13. Gearhart MO & Sorg TB. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. Annals of Pharmacotherapy 1993; 27:285-289.
14. 3 vitamin D. Xth International Conference on AIDS, Milan, Italy, 16-18 March 1994. Abstr. P152.
15. Petterson KJ, Nordgren T & Westerlund D. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed phase liquid chromatography. Journal of Chromatography 1989; 488:447-455.
16. 2+. Scandinavian Journal of Clinical and Laboratory Investigation 1994; 54(Suppl. 217):37-43.
17. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey M & Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. Journal of Clinical Endocrinology & Metabolism 1991; 72:1130-1135.
18. Noormohamed FH, Piner C, Youle MS, Higgs CJ, Gazzard EG & Lant AF. Renal effects of intravenous foscarnet in HIV seropositive patients. Clinical Science (London) 1995; 88(Suppl. 32):15P(Abstr.).
19. Bronner F. Renal calcium transport: mechanisms and regulation - an overview. American Journal of Physiology 1989; 257:F707-F711.
20. Friedman PA & Gesek FA. Calcium transport in renal epithelial cells. American Journal of Physiology 1993; 264:F181-F198.
21. Douchet A & Katz AI. High-affinity Ca-Mg-ATPase along the rabbit nephron. American Journal of Physiology 1982; 242:F346-F352.
22. Zhang A, Cheng TP-O & Altura BM. Magnesium regulates intracellular free ionized calcium concentration and cell geometry in vascular smooth muscle cells. Biochimica et Biophysica Acta Molecular Cell Research 1992; 1134:25-29.
23. Trifillis AL, Cui X & Drusando GL. Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro. Antimicrobial Agents and Chemotherapy 1993; 37:2496-2499.
24. Deray G, Katlama C & Dohin E. Prevention of foscarnet nephrotoxicity. Annals of Internal Medicine 1990; 113:332.
25. Poujoel P, Chabardes D, Roinel N & De Rouffignac C. Influence of extracellular volume expansion on magnesium, 'calcium and phosphate handling along the nephron. Pflügers Archiv 1976; 365:203-211.
26. Sjovall J, Karlson A, Ogenstad S, Sandstorm E & Saarimaki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with immunodeficiency virus. Clinical Pharmacology & Therapeutics 1988; 44:65-73.
27. Sjovall J, Bergdahl S, Mivin G, Ogenstad S & Saarimaki M. Pharmacokinetics of foscarnet and distribution into cerebrospinal fluid after intravenous infusion in patients with human immuno-deficiency virus infection. Antimicrobial Agents and Chemotherapy 1989; 33:1023-1031.